Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Authors
Keywords
Immunotherapy, Immune checkpoint blockade, PD-1, PD-L1, CTLA-4, Gastrointestinal cancers, Esophageal cancer, Gastric cancer, Colorectal cancer, Pancreatic cancer, Hepatocellular carcinoma
Journal
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-04-17
DOI
10.1186/s13045-017-0454-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- (2016) Angus G Dalgleish et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Emerging role of epithelial-mesenchymal transition in hepatic cancer
- (2016) Go J. Yoshida JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
- (2016) Kuo-Hsing Chen et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
- (2016) Lauren Van Der Kraak et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model
- (2015) Samer Bazzi et al. IMMUNOBIOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
- (2015) Andy Yingjie Lin et al. Journal of Hematology & Oncology
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of liver cancer with hepcortespenlisimut-L: open-label Phase II clinical study in patients with advanced HCC
- (2015) Marina G Tarakanovskaya et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Four Subtypes of Gastric Cancer Identified
- (2014) Cancer Discovery
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Cancer immunotherapy in clinical practice��the past, present, and future
- (2014) Gaurav Goel et al. Chinese Journal of Cancer
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
- (2012) Jeffrey M. Hardacre et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
- (2012) William K. Funkhouser et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
- (2012) Hiroaki Saito et al. JOURNAL OF SURGICAL ONCOLOGY
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma
- (2011) Martin Loos et al. ANNALS OF THORACIC SURGERY
- Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
- (2011) N. Halama et al. CANCER RESEARCH
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations
- (2009) David Tougeron et al. MODERN PATHOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now